Crossmark

A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)

Crossref DOI link: https://doi.org/10.1007/s00198-023-06877-6

Published Online: 2023-08-18

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shi, X.

Cheng, Q.

Zhao, Y.-Z.

Zou, S.-P.

Sun, M.-H. https://orcid.org/0000-0002-1556-543X
License Information

Text and Data Mining valid from 2023-08-18

Version of Record valid from 2023-08-18
More Information

Article History

Received: 27 January 2023

Accepted: 1 August 2023

First Online: 18 August 2023

Declarations

:

: None.